Comparative Pharmacology
Head-to-head clinical analysis: TAGAMET versus TAGAMET HB 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAGAMET versus TAGAMET HB 200.
TAGAMET vs TAGAMET HB 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, inhibiting gastric acid secretion. Also reduces pepsin and intrinsic factor secretion.
Competitive antagonist at histamine H2-receptors, inhibiting gastric acid secretion by blocking histamine-mediated stimulation of parietal cells.
400 mg orally twice daily or 800 mg orally at bedtime for duodenal ulcer; 300 mg IV/IM every 6-8 hours.
200 mg orally once or twice daily, not to exceed 400 mg per day.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours (normal renal function); prolonged to 5-10 hours in moderate renal impairment (CrCl <30 mL/min) and up to 20-30 hours in anuria
Terminal elimination half-life: 2-3 hours in patients with normal renal function. In elderly or renal impairment, half-life may extend to 4-5 hours.
Renal: 50-70% unchanged; hepatic metabolism: ~30%; biliary/fecal: minor (<5%)
Renal: 75-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: ~20% as metabolites and unchanged drug.
Category C
Category C
H2 receptor antagonist
H2 receptor antagonist